Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Recruiting · Phase 2 · NCT06561347
Conditions: Waldenstrom Macroglobulinemia
At a glance
- Research payments reported, 2025
- $1.5M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 65
About the trial
- Sponsor
- Massachusetts General Hospital (with BeOne Medicines)
- Tested
- Zanubrutinib (drug), Bendamustine (drug), Rituximab (drug)
- Dates
- Started 2024-12-20; completion 2027-12-01
- Results posted
- Not yet
The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.
From ClinicalTrials.gov, last updated 2026-09-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $1.5M in research payments for this study in 2025 (5 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $1.5M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.